Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3,132.00    48.00 (1.56%)
Bid:
3,130.00
Ask:
3,133.00
Spread: 3.00 (0.096%)
Market Cap: £4.36b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Interim Management Statement

24 Apr 2014 07:00

RNS Number : 3766F
Croda International PLC
24 April 2014
 



24 April 2014

 

Croda International Plc

 

AGM and Interim Management Statement

 

PROFITABILITY IMPROVED DESPITE ADVERSE CURRENCY TRANSLATION

 

 

Croda International Plc today announces its Interim Management Statement for the period since 31 December 2013.

 

Trading

 

The modest but improving growth trend in underlying sales seen in the second half of 2013 continued through the first quarter of 2014, despite the disruption caused by the severe weather in North America and difficult economic conditions in South America. On a constant currency basis, Group turnover was up 2.9% with acquisitions contributing 1.6% to this total. However, adverse currency translation of 6.1% meant that reported sales in sterling were down 3.2% to £274.0m (2013: £283.1m).

 

Group operating profit increased 1.0% to £68.7m (2013: £68.0m). Operating margins increased to 25.1% (2013: 24.0%), reflecting favourable product mix. Return on sales increased to 33.3% (2013: 31.1%) in Consumer Care and to 19.0% (2013: 17.0%) in Performance Technologies as both divisions continued to benefit from strong underlying demand for high value products. Industrial Chemicals' return on sales reduced to 4.7% (2013: 9.1%), reflecting the integration of Sipo and weaker commodity margins generally.

 

Pre-tax profits increased slightly to £65.2m (2013: £65.1m) with a stronger underlying performance offset by a £3.5m impact from adverse currency translation.

 

On a divisional basis, underlying Consumer Care sales decreased by 0.6%. Crop Care was impacted by heavy snow in North America during January and February and weak sales into Eastern Europe. Weak sales in North America and challenging economic conditions in South America were the main reasons behind modest underlying sales declines in Personal Care. Health Care growth was strong in almost all geographies. A further 0.5% contribution to sales growth came from acquisitions.

 

Underlying sales in Performance Technologies were up 3.7%, continuing the improved trend seen in the final quarter of 2013. Business in Asia was particularly strong. All business areas apart from Home Care saw good sales growth. The Sipo acquisition added an additional 1.7% to turnover.

 

Underlying Industrial Chemicals sales were up 2.7% and again, Sipo added a further 7.2% to the growth.

 

Financial Position

 

There has been no significant change in Croda's financial position during the period. Interest costs in the quarter were slightly higher than 2013 due to the consolidation of 100% of Sipo's debt.

 

Underlying cash generation was again strong in the quarter, with net debt falling £13.6m to £188.6m after paying over £20m into the UK pension fund in January.

 

Outlook

 

We expect the modest improvement in underlying sales growth seen in the first quarter to continue. However, adverse currency translation is expected to remain an issue and consequently, second quarter performance is likely to be similar to that seen in the first quarter. The Board is confident that the Group has the right strategy in place to continue to drive profitable underlying growth.

 

 

For further information please contact:

 

Steve Foots/ Sean Christie

Croda International Plc

 

Charlie Armitstead/ Rosie Oddy

Pendomer Communications

 

 

Tel: 01405 860551

 

 

Tel: 020 3603 5220

 

 

The company will host a conference call for analysts at 8.00am (BST) today:

 

Dial-In: +44 (0) 203 426 2888

Please quote "Croda International"to gain access to the call

 

 

Croda International Plc

Unaudited income statement for continuing operations

31 March 2014

 

3 months to

3 months to

31 March

31 March

2014

2013

Change

Revenue

Consumer Care

148.4

158.4

-6.3%

Performance Technologies

93.8

93.9

-0.1%

Industrial Chemicals

31.8

30.8

+3.2%

274.0

283.1

-3.2%

Adjusted operating profit1

Consumer Care

49.4

49.2

+0.4%

Performance Technologies

17.8

16.0

+11.3%

Industrial Chemicals

1.5

2.8

-46.4%

68.7

68.0

+1.0%

Net bank and loan interest payable

(2.3)

(1.7)

Net retirement benefit scheme financing

(1.2)

(1.2)

Adjusted profit before tax1

65.2

65.1

+0.2%

Operating margin

25.1%

24.0%

 

Analysis of turnover uplift for continuing operations:

 

Constant

Currency

Underlying

Acquisitions

Currency

translation

Total

Consumer Care

-0.6%

+0.5%

-0.1%

-6.2%

-6.3%

Performance Technologies

+3.7%

+1.7%

+5.4%

-5.5%

-0.1%

Industrial Chemicals

+2.7%

+7.2%

+9.9%

-6.7%

+3.2%

Total

+1.3%

+1.6%

+2.9%

-6.1%

-3.2%

 

 

 

1 Continuing operations before exceptional items, acquisition costs and amortisation/write off of intangible assets arising on acquisition.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSMMGZDRFNGDZM
Date   Source Headline
19th Oct 202311:19 amRNSHolding(s) in Company
19th Oct 202310:34 amRNSDirector/PDMR Shareholding
12th Oct 202311:46 amRNSDirector/PDMR Shareholding
9th Oct 20237:00 amRNSThird Quarter Trading Update
6th Oct 20234:12 pmRNSDirector/PDMR Shareholding
5th Oct 20238:53 amRNSHolding(s) in Company
3rd Oct 20234:03 pmRNSDirector/PDMR Shareholding
27th Sep 20235:17 pmRNSDirector/PDMR Shareholding
26th Sep 202311:38 amRNSDirector/PDMR Shareholding
22nd Sep 20237:00 amRNSDirectorate Change
15th Sep 202311:51 amRNSDirector/PDMR Shareholding
12th Sep 20234:01 pmRNSDirector/PDMR Shareholding
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update
31st May 20232:47 pmRNSDirector/PDMR Shareholding
26th May 20233:51 pmRNSDirector/PDMR Shareholding
11th May 20234:05 pmRNSDirector/PDMR Shareholding
3rd May 20233:08 pmRNSDirector/PDMR Shareholding
3rd May 20233:00 pmRNSDirector/PDMR Shareholding
2nd May 20232:30 pmRNSDirector/PDMR Shareholding
27th Apr 20239:18 amRNSResult of AGM
24th Apr 20234:49 pmRNSDirector/PDMR Shareholding
12th Apr 20232:00 pmRNSDirector/PDMR Shareholding
28th Mar 20233:51 pmRNSDirector/PDMR Shareholding
28th Mar 20233:50 pmRNSDirector/PDMR Shareholding
28th Mar 20233:47 pmRNSDirector/PDMR Shareholding
28th Mar 20233:46 pmRNSDirector/PDMR Shareholding
28th Mar 20233:44 pmRNSDirector/PDMR Shareholding
28th Mar 20233:42 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
27th Mar 20233:52 pmRNSDirector/PDMR Shareholding
27th Mar 20233:48 pmRNSDirector/PDMR Shareholding
24th Mar 202310:57 amRNSDirector/PDMR Shareholding
24th Mar 202310:31 amRNSDirectorate Change
17th Mar 20235:12 pmRNSAnnual Financial Report
17th Mar 20232:30 pmRNSDirector/PDMR Shareholding
17th Mar 202310:53 amRNSDirector/PDMR Shareholding
13th Mar 20232:02 pmRNSDirector/PDMR Shareholding
3rd Mar 202311:57 amRNSDirector/PDMR Shareholding
28th Feb 20239:21 amRNSDirectorate Change
28th Feb 20237:00 amRNSResults for the year ended 31 December 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.